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S38 Journal of Thoracic Oncology Vol. 11 No. 2Shas potent anti-tumor activity, it has limited clinical
use due to its toxicity. Derivatives of triptolide have
been developed in order to decrease toxicity without
affecting bioavailability. One of these triptolide de-
rivatives, MRx102, has been shown to have antileu-
kemic activity, but the effect of MRx102 in lung cancer
is currently unknown. In this study, we evaluated
MRx102 as a novel therapeutic for lung cancer. We
tested the effect of MRx102 on the proliferation and
survival of non-small cell lung cancer (NSCLC) cell
lines in vitro and the effect on tumor formation and
metastasis in vivo. Mice injected subcutaneously with
H460 lung cancer cells were treated with MRx102 or
carboplatin to determine the effect of MRx102 on tu-
mor formation in comparison to standard treatment.
Patient-derived xenografts (PDX) with different WIF1
expression levels were treated with MRx102 or
cisplatin. We then tested the effects of MRx102
treatment on migration and invasion of lung cancer
cells using Transwell ﬁlters coated with ﬁbronectin
and Matrigel, respectively. Tail vein injections of H460
and A549 cells were used to study the effect of
MRx102 on metastasis. Our studies show the MRx102
decreases proliferation of both H460 and A549 lung
cancer cells and increases apoptosis in the H460 cell
line. Further, MRx102 also signiﬁcantly inhibited
migration and metastasis. We also have shown that
MRx102 potently inhibits the growth of tumors with
low WIF1 expression and decreases Wnt pathway ac-
tivity in vitro. These results indicate that MRx102 has
potent antitumor effects in lung cancer both in vitro
and in vivo, and is a potential novel therapy that tar-
gets the Wnt pathway in NSCLC.Gene expression classiﬁer for
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lung carcinoma (NSCLC) are eligible for adjuvant
chemotherapy, however its efﬁcacy for stage I patients
is still ambiguous. Importantly, adjuvant chemo-
therapy trials in early stage lung cancer patients have
been conducted in unselected patient populations,
which may, in part, explain the lack of conclusive ev-
idence of beneﬁt. There are currently no validated
methods that prospectively identify NSCLC patients at
a high risk of recurrence after surgery. Many gene
expression-based gene signatures that identify pa-
tients with lung adenocarcinoma (ADC) at high-risk of
recurrence have been described. However, data are
still lacking on molecular signatures that stratify risk
of recurrence in patients with Squamous Cell Carci-
noma (SCC), the second most common histological
subtype of NSCLC. SCC is commonly detected in heavy
smokers, where the risk of lung cancer is closely
correlated with tobacco consumption. The disease is
heterogeneous, and patient outcome is complicated by
comorbities such as Chronic Obstructive Pulmonary
Disease and Cardiovascular Disease. The National Lung
Screening Trial (NLST), which compared low-dose
computed tomography (LDCT) versus chest radiog-
raphy, demonstrated a statistically signiﬁcant mortal-
ity beneﬁt of LDCT screening in patients with ADC.
However, there was no beneﬁt for patients with lung
SCC despite an increase in the detection of early stage
tumors. Surgical resection is the recommended treat-
ment for Stage I NSCLC. However, approximately 30%
patients will recur and die within 5 years of surgery.
In view of the high rate of relapse and the lack of
predictive biomarkers, it is critical to develop bio-
markers that can identify high-risk early stage lung
cancer patients who may beneﬁt from adjuvant
chemotherapy or immunotherapy. We present a
prognostic classiﬁer based on gene expression that is
broadly applicable to diverse patient cohorts as a
clinical tool for guiding postoperative management
and therapeutic decisions in patients with early stage
lung SCC. In order to maximize the potential for
discovering functionally relevant biomarkers we
focused our study on genes with known mechanistic
roles in lung SCC development and prognosis. Specif-
ically, the expression of 256 genes selected by a
literature search was evaluated in microarrays from
107 tumors resected from patients with early stage
lung SCC. Genes signiﬁcantly associated with relapse-
free survival by univariable Cox regression were
technically validated by qRT-PCR in the same sample
population and externally validated in an indepen-
dently collected cohort of 91 SCC. A multivariable
regression-based classiﬁer was then established on
genes independently associated with survival in these
February 2016 Abstracts S39two cohorts by incorporating the resulting coefﬁcients
of multivariable Cox regression model into a score that
utilizes linear gene expression values. This gene
expression classiﬁer was validated in 6 additional
publicly available datasets of stage I/II lung SCC (N ¼
358). The classiﬁer identiﬁed high-risk patients in
multiple large-scale and geographically diverse cohorts
(N ¼ 570). The results appear to be independent of
race and gene expression platform. Canonical path-
ways associated with this signature encompass pro-
teins involved in signal transduction, tissue
remodeling, and cell motility that would broadly lead
to cancer cell migration, invasion and proliferation,
suggesting that the gene signature identiﬁes molecular
subsets of patients with clinical relevance. This gene
classiﬁer could be used to guide clinical decisions after
surgical resection. Thus, we would advocate that this
classiﬁer be incorporated into prospective trials for
further evaluation of its clinical effectiveness.A functional SNP in MRPL43 modulates
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miRNAs, a class of non-coding genes, modulate mRNA
translation and stability by primarily binding to the
3’UTR of mRNA transcripts. Genetic variation within a
miRNA gene could modulate the thermodynamic
interaction between the miRNA and its target mRNA
sequence and modulate expression. Many studies have
demonstrated the importance of miRNAs in cancer
biology, including lung cancer. Indeed, we recently
published several studies showing the relationship
between functional SNPs in microRNA binding sites
and the relationship with lung cancer risk and
outcome. However, few studies that systematically
examined SNPs in miRNA genes and their relevance to
lung cancer have been conducted to date to our
knowledge. We conducted a genome-wide analysis ofSNPs in microRNA genes and assessed their relevance
to human lung cancer. Using samples from the NCI-MD
study, we examined 22 SNPs (after selections pro-
cedures) in 974 European Americans and found that
rs4919510 (Chr10 q24.31) in miR-608 was associated
with a 2.55 fold increased risk of lung cancer, after
adjustment for age, gender, pack-years of smoking and
smoking status (OR 2.55 95% C.I. 1.04-6.28; P¼0.041).
The G allele of rs4910510 is common; the MAF is
18%, 57% and 53% in European Americans, African
Americans and Japanese, respectively. We therefore
tested for population conversion of this epidemiolog-
ical observation in 2 other geographical populations,
i.e., an African American population and a Japanese
population. In both studies, the G allele of rs4919510
was associated with an increased risk of lung cancer
(African American: OR 2.73, 95% C.I. 1.44-5.14;
P¼0.002; n¼566) (Japanese: OR 1.85, 95% C.I. 1.18-
2.86; P¼0.007; n¼768). We also found that rs4910510
was associated with lung cancer survival. The GG ge-
notype of rs4919510 was signiﬁcantly associated with
prolonged survival among European Americans (HR
0.15, 95% C.I. 0.04-0.62; P¼0.008) and Japanese pa-
tients (HR 0.66, 95% C.I. 0.45-0.97; P¼0.036), while a
similar trend was observed in African Americans (HR
0.64, 95% C.I. 0.35-1.16; P¼0.1). An eQTL analysis
using samples from the NCI-MD study found that the
SNP did not affect miR-608 processing and functional
studies comparing the function of miR-608-C and with
miR-608G did not reveal any differences in either
mRNA targeting or function. We subsequently mapped
the functional signiﬁcance of the rs4919510 associa-
tion to a neighboring gene, MRPL43, which is a
component of the mitochondrial ribosome. Our results
show the miR-608 SNP is actually in linkage with a
SNP in MRPL43 that creates a donor splice site at the
exon 3/intron 3 boundary. Thus, rs4919510 is a tag
allele for the real functional locus in MRPL43. The SNP
changes the splicing pattern of MRPL43, whereby
expression of the short and predominant isoform is
decreased, and the longer isoforms is increased
(P<0.0001). We replicated this observation in two
different lung cancer tissue sets and also 6 other tis-
sue types using TCGA data (all P<00001) and also
across populations of different ancestry. We further
found that the SNP modulates mitochondrial meta-
bolism by altering the balance between oxidative
phosphorylation and glycolysis. Our initial study
aimed to evaluate the association between microRNA
SNPs and lung cancer. In summary, we did not
observe a strong relationship between miRNA SNPs
with either lung cancer risk or survival. However, we
have identiﬁed a SNP in MRPL43, a subunit of the
mitochondrial ribosome, which is associated with risk
